Research Use Only
Semaglutide vs Liraglutide
Neutral RUO comparison of Semaglutide and Liraglutide using public protocol-library fields: vial size, research class, mechanism, evidence level and references.
Public fields onlyReferences included
This page compares only public, research-context fields from the AllPeptides protocol library. It is not a ranking, recommendation, safety comparison or human-use guide.
Public research comparison fields
| Field | Semaglutide | Liraglutide |
|---|---|---|
| Name | Semaglutide | Liraglutide |
| Representative vial size | 2.5mg | 3mg |
| Research class | Metabolic research | Metabolic research |
| Mechanism context | Semaglutide mimics GLP-1, enhancing glucose-dependent insulin secretion, reducing glucagon, slowing gastric emptying and reducing appetite through central mechanisms. | Liraglutide mimics GLP-1, enhancing glucose-dependent insulin, reducing glucagon, slowing gastric emptying and reducing appetite. It differs from semaglutide in half-life (~13 hours vs ~7 days). |
| Evidence level | Not specified in profile | Not specified in profile |
Combined references
- NEJM — STEP 1 — Semaglutide 2.4mg for obesity
View source - NEJM — SELECT — Semaglutide cardiovascular benefits
View source - Pi-Sunyer X et al. N Engl J Med 2015 — A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
View source - NEJM — LEADER — Liraglutide cardiovascular outcomes
View source